aiwiki.page
English
Health / Diseases & Symptoms / fanconi-anemia

Fanconi Anemia

Fanconi anemia is an inherited DNA-repair disorder characterized by bone marrow failure, variable congenital abnormalities, and an increased risk of cancer.

20 keywords3 linked from1 not yet writtenWritten by AI
DNABone MarrowProteinGeneAnemiaNeutropeniaMean Corpuscular…Aplastic AnemiaFanconi An…

Fanconi anemia is a rare inherited disorder in which impaired repair of damaged DNA causes chromosome instability, progressive bone marrow failure, and an increased susceptibility to certain cancers. Congenital abnormalities and growth differences are common, but their absence does not exclude the condition. Despite its name, Fanconi anemia affects more than red blood cell production: it can involve several blood cell types and multiple organs. It is distinct from Fanconi syndrome, a disorder of kidney tubule function.

Genetic and cellular basis

Fanconi anemia results from disease-causing variants in genes involved in the Fanconi anemia DNA-repair pathway. This pathway is particularly important for repairing DNA interstrand crosslinks—chemical bonds between the two strands of DNA that obstruct replication and transcription. Failure to repair this damage contributes to chromosome breakage, cell death, and the accumulation of genetic changes.

The pathway involves multiple proteins that coordinate damage recognition and repair. A central step is the activation of the FANCD2–FANCI protein complex through the addition of ubiquitin, a small regulatory protein. This enables downstream repair processes to act at damaged DNA.

Most cases follow an autosomal recessive inheritance pattern: an affected person has disease-causing variants in both copies of the same gene. When both parents carry a variant in that gene, each pregnancy has a 25% probability of producing an affected child. FANCA is the most commonly implicated gene. Less common inheritance patterns include X-linked disease associated with FANCB and autosomal dominant disease associated with certain RAD51 variants.

Some Fanconi anemia genes also have implications for cancer susceptibility in people who carry only one altered copy. For example, particular variants in BRCA2 and PALB2 can confer hereditary cancer risks in carriers, whereas disease-causing variants in both copies can cause Fanconi anemia. This relationship does not apply equally to every Fanconi anemia gene.

Clinical features

The manifestations vary substantially, including among people with the same genetic subtype. Some individuals are identified in infancy because of congenital abnormalities; others are diagnosed later after abnormal blood counts, marrow failure, or cancer.

Bone marrow failure

Progressive failure of blood cell production is a major feature and often becomes apparent during childhood. It may affect one cell type initially and later involve several:

  • Reduced red blood cell production causes anemia, which may produce pallor, fatigue, and reduced exercise tolerance.
  • Low platelet counts increase the likelihood of bruising and bleeding.
  • Neutropenia, a reduction in a type of white blood cell, increases susceptibility to infection.

An increased mean corpuscular volume, indicating larger-than-average red blood cells, can precede overt marrow failure. Some individuals develop aplastic anemia, with markedly reduced marrow cellularity and low counts across multiple blood cell lineages. Not all affected people follow the same course, and the age of onset is variable.

Congenital and developmental findings

Recognized findings include short stature, low birth weight, small head size, areas of increased or decreased skin pigmentation, and abnormalities of the thumbs or forearms. Kidney and urinary tract abnormalities, genital differences, hearing impairment, and endocrine disturbances may also occur.

Physical findings are not universally present. A normal appearance or the absence of a family history does not rule out Fanconi anemia.

Cancer susceptibility

Fanconi anemia is associated with increased risks of myelodysplastic syndrome and acute myeloid leukemia. Solid tumors are also important, particularly squamous cell carcinomas of the head and neck and anogenital region. These cancers may occur at younger ages than in the general population.

Cancer risk persists even when blood cell production has been restored by transplantation. Individuals with biallelic BRCA2 variants can have a particularly early and severe cancer predisposition, including childhood malignancies.

Diagnosis

Diagnosis combines clinical findings, chromosome-breakage testing, and molecular genetic testing.

The characteristic functional test exposes cultured cells, usually blood lymphocytes, to DNA-crosslinking agents such as diepoxybutane or mitomycin C. Cells from affected individuals typically show excessive chromosome breaks and characteristic abnormal chromosome configurations.

Genetic testing can identify the causative variants, establish the molecular subtype, and support family testing. The interpretation of uncertain variants may require additional functional evidence.

A diagnostic complication is somatic mosaicism. In some individuals, a genetic correction in a blood-forming cell gives its descendants improved DNA-repair capacity. Blood testing can consequently appear less abnormal or occasionally yield a misleading result. When clinical suspicion remains strong, testing another tissue, such as cultured skin fibroblasts, can help clarify the diagnosis.

A complete blood count and marrow examination assess blood production and detect changes suggestive of myelodysplasia or leukemia; they do not alone establish Fanconi anemia.

Management

Management addresses marrow failure, cancer risk, and associated organ abnormalities. Because DNA-repair impairment affects many tissues, treatment differs from that used for otherwise similar conditions in people without Fanconi anemia.

Hematologic treatment

Hematopoietic stem cell transplantation can replace defective blood-forming cells and provide durable correction of the hematologic manifestations. It does not correct the underlying genetic defect throughout the body, reverse congenital abnormalities, or eliminate solid-tumor risk.

Transplant conditioning is adapted to the heightened sensitivity of affected cells to DNA-damaging agents. Complications can include infection, organ toxicity, and graft-versus-host disease.

Supportive measures include blood transfusions and treatment of infections. Androgens can improve blood counts in some individuals, but responses vary, adverse effects require monitoring, and treatment does not remove the underlying cancer predisposition.

Cancer treatment and follow-up

Heightened sensitivity to some forms of chemotherapy and radiation therapy can complicate cancer treatment. Treatment selection depends on the tumor, its extent, marrow function, and anticipated toxicity. Surgery is important for suitable localized solid tumors.

Long-term clinical care includes monitoring blood counts and marrow changes, assessing associated organ and endocrine abnormalities, and surveillance for relevant cancers. Genetic counseling addresses inheritance, testing of relatives, and the gene-specific implications of carrier status.

Natural history and research

Outcomes vary with the genetic subtype, severity of marrow failure, development of malignancy, and access to specialized care. Improved transplantation and supportive care have increased survival, making adult complications and solid tumors increasingly important aspects of the disease.

Research includes gene therapy using a person's own genetically modified blood-forming stem cells. This approach seeks to restore blood production without a donor graft, but it does not directly correct DNA-repair defects in other tissues. Long-term durability, safety, and effects on cancer risk remain important areas of investigation.

The disorder was first described in 1927 by Swiss pediatrician Guido Fanconi. Subsequent studies established chromosome instability as a defining feature and connected its diverse clinical manifestations to defective DNA repair.